Together, these findings demonstrate that Vidu treatment expands the number of intratumoral and circulating tumor-specific CD8+ T cells and that the number of tumor-specific CD8+ T cells and the antitumor response is sustained by the addition of αPD-1. Here, CD8A is linked to neoplasm.